Cryopreservation has gone beyond just "freezing cells." Today it is a key technology for enabling cell therapies, biobanks, transplants, and clinical research on a global scale. The evolution of protocols, cryoprotectants, equipment, and quality control is shortening the gap between biological material collection and its future use — with safety, traceability, and predictability.
In this article, I explain the most relevant advances in cryopreservation, the size of the cryobiology/biobank market, and why families in the United States and various European countries continue to opt for umbilical cord cell storage — despite medical recommendations calling for informed decision-making and often prioritizing public donation when available.
Practical summary for those researching the topic
- Modern cryopreservation combines ice science (or its prevention), cryoprotectant materials, precise thermal control, and digital chain-of-custody.
- Cord blood has been used in tens of thousands of transplants worldwide, with significant global inventory in public and family/private banks.
- Market: industry reports estimate tens of billions of dollars for biobanks and storage/biobanking services, with consistent growth over the decade.
- USA vs Europe: the US has a strong private model presence and commercial scale; Europe has more regulatory variation (in some countries, greater focus on public donation and restrictions on private models).
What is cryopreservation (and why is it so hard to do well)
Cryopreservation is maintaining cells and tissues at very low temperatures to "pause" metabolism and preserve viability and function for long periods. The challenge is not reaching the cold — it is crossing the path to get there: controlling ice formation, cellular dehydration, osmotic shock, cryoprotectant toxicity, and damage during rewarming/thawing.
In practice, cryopreservation quality depends on three pillars:
5 advances changing cryobiology now
1) Vitrification and the "rewarming problem"
Vitrification seeks to avoid ice crystals by bringing the sample to a "vitreous" (glass-like) state. The historical bottleneck was rewarming larger volumes without thermal cracking or recrystallization. Work with nanowarming (inductive heating with magnetic nanoparticles) has shown important gains in rewarming uniformity in vitrified tissues, paving the way for more ambitious applications in tissue and, in the future, organ preservation.
2) New cryoprotectants and reduced toxicity (less DMSO)
DMSO is a classic cryoprotectant but has limitations and adverse effects depending on the application. Recent literature reinforces interest in reducing DMSO concentration and/or combining strategies (other agents, ready-made media, additives) to preserve viability with lower toxicity.
3) Ice recrystallization inhibitors
Even when freezing is "well done," crystals can grow during thermal oscillations or thawing. Recrystallization inhibition strategies (including polymers and molecules with anti-freeze effects) are gaining ground as a way to increase consistency and reduce post-thaw losses.
4) Global standardization and quality auditing in cell banks
In cord blood, for example, international standards (like NetCord-FACT) reinforce quality requirements, clinical data, traceability, and consistent laboratory practices — something central to confidence in biological materials stored for long periods.
5) More robust cold chain and cryogenic logistics
"Real" cryobiology is an end-to-end operation: collection → controlled transport → processing → cryopreservation → storage → release. Logistical and regulatory maturity (including licensing requirements in some countries) has raised the industry standard.
Umbilical cord blood: why it remains relevant
Cord blood is a source of hematopoietic stem cells, used for decades in transplants. The international industry association (Cord Blood Association) indicates more than 60,000 transplants performed worldwide.
Furthermore, a review in Bone Marrow Transplantation describes the scale already achieved: tens of thousands of transplants, with about 800,000 units in public banks and over 4 million in private/family banks globally.
In the US, federal program data linked to the donor registry points to more than 246,500 cord blood units in the registry, including units collected via the National Cord Blood Inventory (NCBI).
The size of the cryobiology, cryopreservation, and cell storage market
Since "cryobiology" can mean different things (cryopreservation equipment, supplies, services, biobanks, cell/tissue banks), numbers vary by methodology. Still, there is consensus that it is a large and growing sector.
| Segment | Estimated Size | Projection | Source |
|---|---|---|---|
| Cord blood banking services | US$ 26.99 B (2024) | US$ 41.36 B (2030) | Grand View Research |
| Cell cryopreservation (market) | US$ 3.38 B (2024) | US$ 8.86 B (2033) | Grand View Research |
| Biobanks (market) | US$ 86.82 B (2025) | US$ 160.54 B (2033) | Grand View Research |
Transparency note: some market intelligence providers estimate higher values for "cell cryopreservation" depending on what is included. This does not mean anyone is "wrong" — it means the market perimeter changes.
Why families in the US and Europe choose cord storage
What usually weighs in the decision (in practice)
Even with medical recommendations for informed decision-making and, in general, encouragement for public donation when possible, many families choose family storage for reasons such as:
- Perception of "biological insurance" for future situations (especially when there is family history).
- Growth of cell therapies and personalized medicine, which increases interest in stored biological materials.
- Compatibility issues: genetic diversity and difficulty finding donors in some groups.
USA: commercial scale and coexistence with public banks
In the US, the public vs. private discussion is well established. ACOG describes both models and reinforces the importance of guiding patients about benefits and limitations of each. The American Academy of Pediatrics also emphasizes education and advantages of public banking.
Europe: more heterogeneous scenario and, in some countries, more restrictive to "private"
In Europe, rules vary significantly by country. In Italy, legislation does not allow private banks in the territory. In the UK, the HTA licenses cord-related activities and there are licensed public and private bank options.
How to choose a storage service with objective criteria
- 1Applicable standards and accreditations (e.g., NetCord-FACT for cord).
- 2Closed and traceable process (chain of custody, identification, records, auditing).
- 3Stability control plan and clear release criteria.
- 4Transparency: what is stored, for how long, how it is monitored.
Frequently Asked Questions (AEO)
Conclusion
Cryobiology has entered a phase where technical advances (such as vitrification with modern rewarming strategies), innovation in cryoprotectants, and regulatory/operational maturity make biological material storage more reliable and scalable.
In the case of cord blood, the topic remains relevant for three objective reasons: clinical history in transplants, significant global stocks (public and family), and a cell therapy ecosystem that grows along with the need for good cryopreservation solutions.
Luís Eduardo da Cruz
Cryopraxis
References (auditable)
- Mazur P. Principles of Cryobiology (chapter in Life in the Frozen State).
- Wowk B. Thermodynamic aspects of vitrification (Cryobiology).
- Manuchehrabadi N. et al. Improved tissue cryopreservation using inductive heating of magnetic nanoparticles (Science Translational Medicine).
- Review: Ice Inhibition for Cryopreservation: Materials, Strategies, and Applications (Advanced Science).
- Cord Blood Association — Fact Sheet (mention of >60,000 transplants).
- Ballen K. et al. Cord blood research, banking, and transplantation (Bone Marrow Transplantation, 2019).
- HRSA / C.W. Bill Young Cell Transplantation Program — registry statistics.
- ACOG — Umbilical Cord Blood Banking (Committee Opinion, 2019).
- American Academy of Pediatrics — Cord Blood Banking (Pediatrics, 2017).
- Centro Nazionale Sangue (Italy) — private bank rules.
- Human Tissue Authority (UK) — regulation/licensing.
- Grand View Research — market size: cord blood, cell cryopreservation, biobanks.
- European Commission / EGE — Opinion No. 19 (ethical aspects).
Follow Axis Biotec
Connect with us on LinkedIn
Get updates on science, regulation, and innovation in advanced therapies straight from our institutional feed.